Buy or sell Rubius Therapeutics stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Rubius Therapeutics Stock

Rubius is developing a new class of drugs, Red-Cell Therapeutics™,

Founded

2013

Notable Investors

Flagship Pioneering

Headquarters

Cambridge MA, US

Total Funding

$145M

About Rubius Therapeutics Stock

VentureLabs has been creating breakthrough companies since 2000. It is the first institution dedicated to entrepreneurial innovation, where discovery, invention and entrepreneuring are performed simultaneously by a world-class team of scientists, innovators and professional entrepreneurs. VentureLabs innovates, invents, launches and builds startups through a unique, systematic approach that produces best-in-class companies based on in-house innovations. VentureLabs has started 35 life science and technology companies, including Joule Unlimited, Seres Therapeutics (NASDAQ: MCRB), Pronutria Biosciences, Symbiota and Moderna Therapeutics.

Investors

Funding History

December 2015$25.0M
June 2017$120M

Management

Senior Vice President, Corporate Development

Nathan Dowden

Co-Founder and Chief Innovation Officer

Avak Kahvejian

Chief Scientific Officer

Robert J Deans

President

Torben Straight Nissen

Press

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Rubius Therapeutics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 100K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo